Summary
CRSP at a glance
CRISPR Therapeutics (CRSP) holds a Quant grade of D (model v1, Oct 30), on a scale from S, the best, to D. It closed at $51.42 on Oct 30, 2026, overvalued by 158% vs model: EV/Revenue · peers puts it at $19.90 a share. The median analyst target is $60.00 from 9 firms.
In Q2 FY2026, the latest quarter on file, revenue grew 1041% on a year earlier to $10.2M, with an operating margin of −1127.6%. Over the twelve months to Q2 FY2026, free cash flow was -$373.8M.
Insiders sold $4.9M and made no open-market purchases over the last 90 days. The latest filing is an 8-K (current report), filed Oct 19.
Price and model value
What the marks mean
Valuation
All 1 models →CRISPR Therapeutics closed at $51.42, overvalued by 158% vs model (EV/Revenue · peers, 19.90).
EV/Revenue · peers leads because DCF · Perpetuity growth · 5y could not lead: the cash-flow gate is shut (an operating loss, or three years of free cash flow summing below zero); P/E · peers does not describe this kind of business; EV/EBITDA · peers could not run on the filed statements.
- Other models
- —
- Wall St. target
- 60.00 14% below
- Above model, past year
- 0 of 0 days
- Valued as
- Loss-Making
Every model
| EV/Revenue · peersused | $19.90 | 158% overvalued |
Against its peers and its past
| CRSP | Peers' median | Own 5-yr median | |
|---|---|---|---|
| P/E · last fiscal year | — | 28.7× | 15.2× |
| Free cash flow yield | −7.0% | 3.3% | |
| Operating margin | −16191.4% | 22.0% | |
| Revenue growth | −90.0% | 5.5% |
Peers are the comparable companies below; the five-year median is at each fiscal year's close.
What the price implies
No growth rate solves for the price: no positive fcf. The reverse DCF →
- Risk-free rate
- 4.94%
- Beta × equity premium
- 1.51 × 4.14%
- Cost of equity
- 11.19%
- Cost of debt
- 4.94%
- Equity weight
- 96%
- WACC
- 10.89%
Quant
Quant grade over time →Quant grade D from model v1, set before the Oct 30 open. S is the best, D the worst. What the grade means
- VRTXA
- ALNYS
- MRNAD
- BIIBB
- REGNB
- INCYS
Growth and forecasts
Every estimate →Analysts expect revenue to grow 428.4% a year over the next 3 years, against 37.3% a year over the last five.
| Revenue | Growth | EPS | Growth | Analysts | |
|---|---|---|---|---|---|
| FY2024 | $35.0M | −90.5% | -$4.34 | — | reported |
| FY2025 | $3.5M | −90.0% | -$6.47 | — | reported |
| FY2026E | $40.4M | +1051.7% | -$4.36 | — | 15 |
| FY2027E | $138.6M | +242.8% | -$3.33 | — | 14 |
| FY2028E | $518.0M | +273.8% | -$2.01 | — | 12 |
- Revenue, last 5 years
- 37.3% a year
- Consensus, next 3 years
- 428.4% a year
The analysts' estimates, as FMP collects them — their figures, not this site's. Reported EPS is GAAP diluted.
Financials
Full statements →In Q2 FY2026, the latest quarter on file, revenue grew 1041% on a year earlier to $10.2M, with an operating margin of −1127.6%. Over the twelve months to Q2 FY2026, free cash flow was -$373.8M.
| Latest | Year before | Change | |
|---|---|---|---|
| Revenue | $13.4M | $37.4M | −64% |
| Operating income | -$531.9M | -$456.2M | n/m |
| Net income | -$451.1M | -$467.8M | n/m |
| Free cash flow | -$373.8M | -$325.6M | n/m |
| Diluted EPS | -$4.71 | -$5.43 | n/m |
- Cash and investments
- $2.4B
- Total debt
- $783.7M
Profitability and health
Every ratio →Operating margin −16191.4% in fiscal 2025, against 40.9% in 2021; net cash of $1.6B at the latest quarter.
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Trend | |
|---|---|---|---|---|---|---|
| Gross margin | 88.9% | −25186.7% | 64.8% | −215.0% | −6537.0% | |
| Operating margin | 40.9% | −154394.7% | −60.1% | −1333.0% | −16191.4% | |
| Net margin | 41.4% | −149122.7% | −41.5% | −1046.4% | −16569.8% | |
| Return on equity | 15.7% | −34.7% | −8.2% | −19.0% | −30.3% | |
| Debt to equity | 0.09× | 0.13× | 0.13× | 0.12× | 0.21× | |
| Interest coverage | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× | |
| Current ratio | 20.17× | 15.30× | 17.54× | 22.07× | 13.32× |
Peers
Peers in full →CRSP beside 6 comparable companies, chosen by business, not by industry label.
| Company | Market value | P/E | FCF yield | Gross margin | Op. margin | Revenue growth | Valuation | Quant |
|---|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $5.0B | n/m | −7.0% | −6537.0% | −16191.4% | −90.0% | – | D |
| VRTX Vertex Pharmaceuticals Incorporated | $141.7B | 36.5× | 2.3% | 85.0% | 39.4% | +9.6% | B | A |
| REGN Regeneron Pharmaceuticals, Inc. | $95.5B | 22.4× | 4.3% | 85.4% | 24.9% | +1.0% | A | B |
| MRNA Moderna, Inc. | $88.5B | n/m | −2.3% | 55.4% | −158.1% | −39.2% | – | D |
| BIIB Biogen Inc. | $37.5B | 28.7× | 5.5% | 70.5% | 19.1% | +1.4% | S | B |
| INCY Incyte Corporation | $24.5B | 18.8× | 5.5% | 92.8% | 26.1% | +21.2% | B | S |
| ALNY Alnylam Pharmaceuticals, Inc. | $22.1B | 70.8× | 2.1% | 81.8% | 13.5% | +65.2% | S | S |
Ownership
Every holder →Wall Street
Every firm →9 firms published a price target in the last 365 days: the median is $60.00, 17% above the close.
Third-party ratings and targets, quoted as the firms published them — not this site's view.
Analyst actions
News and filings
All news →Recent
About
Company profile →CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
- CEO
- Samarth Kulkarni
- Employees
- 393
- Headquarters
- Zug, ZG
- Listed
- 2016
Research on CRSP
Model estimates and grades for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; each section is explained in the manual.